Results 41 to 50 of about 10,308 (152)
Roles of TIF1β in Leukemic Stem Cell Through SETDB1‐Dependent and Independent Mechanisms
Cancer Science, Volume 117, Issue 4, Page 896-903, April 2026.In leukemic stem cell, BCR::ABL cooperates with TIF1β to open chromatin at oncogenes and close chromatin at differentiation regulators, driving leukemic reprogramming. In TIF1β‐deficient stem cell, the loss of TIF1β inverts this balance, showing closed chromatin at oncogenes and open chromatin at differentiation regulators.
Mariko Morii, Sho Kubota, Goro Sashida
wiley +1 more source
Research progress in animal models of dry eye disease: Types, mechanisms, and application prospects
Animal Models and Experimental Medicine, Volume 9, Issue 3, Page 462-485, March 2026.Pivotal multifactorial animal models for translational dry eye disease research. Abstract Dry eye disease (DED) is a prevalent and complex multifactorial ocular surface disorder, leading to significant visual discomfort and diminished quality of life.
Jinshen Liu +12 more
wiley +1 more source
The teratogenic effects of imatinib mesylate on rat fetuses
Toxicology Reports, 2015 Imatinib mesylate, a selective tyrosine kinase inhibitor, is the first line treatment against chronic myelogenous leukemia and gastrointestinal stromal tumors.
M.M. El Gendy +3 more
doaj +1 more source
Clinical Case Reports, Volume 14, Issue 2, February 2026.ABSTRACT The aim of this case report is to introduce the reader to dermatofibrosarcoma protuberans (DFSP). In addition to the general characteristics of this rare skin tumor with possible metastatic potential, we also describe an atypical genetic finding that made our patient's case unique.
Jakub Bejbl +3 more
wiley +1 more source
Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
Acta Medica, 2003 The publication provides an up-to-date review of the significance of cytogenetic abnormalities in chronic myelogenous leukemia (CML) and the development of a promising agent with specific molecular target against tyrosine kinase, product of the BCR-ABL ...
Ladislav Chrobák, Jaroslava Voglová
doaj +1 more source
Cancer Reports, Volume 9, Issue 1, January 2026.ABSTRACT Background Dasatinib, a potent second‐generation tyrosine kinase inhibitor (TKI), is highly effective in chronic myeloid leukemia in chronic phase (CML‐CP) resistant to imatinib at standard dosing (100 mg daily), but is often limited by adverse events.
Nandhini Gangadaran +9 more
wiley +1 more source
Periorbital edema secondary to imatinib mesylate
Clinical Ophthalmology, 2010 Collin M McClelland, George J Harocopos, Philip L CusterSchool of Medicine, Washington University, St. Louis, MO, USAAbstract: Imatinib mesylate (Gleevec®) is a well-established pharmacologic treatment for all phases of chronic myeloid leukemia ...
Collin M McClelland +2 more
doaj
Serious Skin Reaction Associated with Imatinib in a Patient with Chronic Myeloid Leukemia
Eurasian Journal of Medicine, 2019 Imatinib mesylate (STI 571) is one of the fundamental chemotherapeutic agents used in the treatment of the chronic, accelerated and blastic phases of chronic myelocytic leukemia (CML), gastrointestinal stromal tumors and Philadelphia chromosome–positive ...
Murat Albayrak +6 more
doaj +1 more source
Genetic Analysis of Imatinib Resistance in CML: The Role of T315I and E255K
Advances in Hematology, Volume 2026, Issue 1, 2026.Background and Aims Imatinib mesylate is a small molecule inhibitor targeting the BCR‐ABL tyrosine kinase. However, some CML patients develop resistance to imatinib. This resistance is commonly associated with mutations in the kinase domain of BCR‐ABL, notably the prevalent T315I and E255K mutations.
Saba Yari +4 more
wiley +1 more source
Impact of Imatinib Therapy on Immunometabolism to Promote β‐Cell Survival in Diabetes
Journal of Diabetes, Volume 18, Issue 7, July 2026.
Sandeep Kumar, Reena Kumari
wiley +1 more source